Delcath Systems has entered into an agreement with the European Institute of Oncology (IEO) to introduce its Hepatic Chemosat Delivery system.
Delcath will provide the IEO with logistics and clinical training support in the performance of chemosaturation therapy using the Chemosat system, as per the agreement.
Delcath’s system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents.
IEO Division of Melanoma and Skin-Muscle Sarcoma director and surgical oncologist Alessandro Testori said their team is excited to be among the first cancer centers in Europe to begin using the Chemosat system.
"We’re eager to begin providing therapy to our patients suffering from melanoma and other metastases in the liver," Testori said.